Zoll Medical, an Asahi Kasei Group Company that manufactures medical devices and related software solutions, has acquired TherOx—a company on improving treatment of acute myocardial infarction and markets systems to deliver super saturated oxygen (SSO2) therapy.
A press release reports that SSO2 therapy, which was recently approved by the US Federal Drug Administration (FDA), has been demonstrated to reduce infarct size after primary coronary intervention (PCI) with stenting in patients with left anterior descending ST-elevation myocardial infarction (STEMI).
Neil Johnston, president of ZOLL Circulation, comments: “Zoll and TherOx are both focused on emergency cardiac care. This acquisition expands the Zoll product portfolio in support of excellence for patients and caregivers.”
Kevin T Larkin, president and CEO of TherOx, says: “SSO2 therapy can help reduce infarct size among patients who suffer from large anterior acute myocardial infarction, which are the most serious heart attacks. Adjunctive to PCI, SSO2 Therapy is intended to salvage heart muscle and reduce infarct size. We are looking forward to becoming part of Zoll, so that together we can bring this breakthrough treatment option to more patients sooner.”